DEA disagrees with firm's meth-resistant claims

The Drug Enforcement Administration says a suburban St. Louis pharmaceutical company is wrong for marketing its pseudoephedrine product to imply methamphetamine cannot be made with it.

But Westport Pharmaceuticals insists its Zephrex-D is impractical as an ingredient for meth, even if small amounts of the drug can be extracted from it. The Maryland Heights, Mo., company began selling the cold and allergy medication last year.

The DEA's acting special agent in charge of the St. Louis office, James Shroba, sent Westport a letter dated May 6 and called the company out on its marketing of Zephrex-D as meth-resistant.

Westport spokeswoman Emilie Dolan said Tuesday that only small amounts of meth can be extracted. She says it would cost meth-makers $250 to $500 to make a single dose using Zephrex-D.


Explore further

Teen girls less successful than boys at quitting meth, pilot study says

© 2013 The Associated Press. All rights reserved.

Citation: DEA disagrees with firm's meth-resistant claims (2013, May 29) retrieved 21 August 2019 from https://medicalxpress.com/news/2013-05-dea-firm-meth-resistant.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more